PURPOSE: Investigation of the effects of breathing motion- and misregistration-induced errors on the superficial dose in the treatment of breast cancer using helical tomotherapy (HT). MATERIAL AND METHODS: Surface dose measurements were performed with thermoluminescence dosimetry (TLD). Two treatment plans with different planning target volume (PTV) definitions of the left breast were used: PTVskin had its ventral border exactly on skin level, while PTVair included also a 10-mm extension ventral to the PTVskin. With a thoracic static phantom, misregistration errors in an HT were simulated. A dynamic phantom was used to simulate a breathing patient during HT. Surface doses of breast cancer patients were measured both for an HT (179 points) and a conventional three-dimensional conformal treatment (70 points). RESULTS: In the static phantom misregistration setup, dose deviations of -31.9% for PTVskin to +35.4% for PTVair could be observed. The dynamic phantom measurements resulted in surface dose deviations from those in a static position between 0.8% and 3.8% without a significant difference for the PTV definitions. The measured surface doses on patients averaged (mean +/- standard deviation) 1.65 +/- 0.13 Gy for the HT and 1.42 +/- 0.11 Gy for the three-dimensional conformal treatment. CONCLUSION: HT enables a homogeneous and reproducible surface dose with small dose deviations in the treatment of breast cancer. HT is a feasible method to treat breast cancer under free shallow breathing of the patient using a treatment plan with a ventral PTV border on the skin level.
PURPOSE: Investigation of the effects of breathing motion- and misregistration-induced errors on the superficial dose in the treatment of breast cancer using helical tomotherapy (HT). MATERIAL AND METHODS: Surface dose measurements were performed with thermoluminescence dosimetry (TLD). Two treatment plans with different planning target volume (PTV) definitions of the left breast were used: PTVskin had its ventral border exactly on skin level, while PTVair included also a 10-mm extension ventral to the PTVskin. With a thoracic static phantom, misregistration errors in an HT were simulated. A dynamic phantom was used to simulate a breathing patient during HT. Surface doses of breast cancerpatients were measured both for an HT (179 points) and a conventional three-dimensional conformal treatment (70 points). RESULTS: In the static phantom misregistration setup, dose deviations of -31.9% for PTVskin to +35.4% for PTVair could be observed. The dynamic phantom measurements resulted in surface dose deviations from those in a static position between 0.8% and 3.8% without a significant difference for the PTV definitions. The measured surface doses on patients averaged (mean +/- standard deviation) 1.65 +/- 0.13 Gy for the HT and 1.42 +/- 0.11 Gy for the three-dimensional conformal treatment. CONCLUSION: HT enables a homogeneous and reproducible surface dose with small dose deviations in the treatment of breast cancer. HT is a feasible method to treat breast cancer under free shallow breathing of the patient using a treatment plan with a ventral PTV border on the skin level.
Authors: M W Kissick; J Fenwick; J A James; R Jeraj; J M Kapatoes; H Keller; T R Mackie; G Olivera; E T Soisson Journal: Med Phys Date: 2005-05 Impact factor: 4.071
Authors: T R Mackie; T Holmes; S Swerdloff; P Reckwerdt; J O Deasy; J Yang; B Paliwal; T Kinsella Journal: Med Phys Date: 1993 Nov-Dec Impact factor: 4.071
Authors: Giuseppe Roberto D'Agostino; Rosa Autorino; Angelo Pompucci; Maria Carmen De Santis; Stefania Manfrida; Giuseppe Di Lella; Giovanna Mantini; Vincenzo Frascino; Silvia Chiesa; Alessio Albanese; Nicola Dinapoli; Luigi Azario; Alba Fiorentino; Vincenzo Valentini; Carmelo Anile; Mario Balducci Journal: Strahlenther Onkol Date: 2011-06-28 Impact factor: 3.621
Authors: Rudolf Klepper; Sebastian Höfel; Ulrike Botha; Peter Köhler; Felix Zwicker Journal: J Appl Clin Med Phys Date: 2014-07-08 Impact factor: 2.102